About this trial
This trial looks at using a mix of treatments for bile duct cancer that cannot be removed with surgery. The treatments include Y-90 radiation, Durvalumab (an immunotherapy), and two chemotherapy drugs: Gemcitabine and Cisplatin. The goal is to see how well these treatments work together and if they are safe for patients.
This is a Phase 2 trial, meaning it is looking at how well the treatment works and its safety. The trial includes about 30 participants. It is regulated by the FDA.
Who can join
This study is open to men and women who are 18 years or older. Participants need to have a type of bile duct cancer that cannot be removed with surgery. They should be able to understand the study and sign a consent form. The trial team will confirm who meets the eligibility criteria.
Conditions
Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic, Metastatic Intrahepatic Cholangiocarcinoma
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Everyone in the study will receive the same treatment. Participants will take Gemcitabine and Cisplatin on specific days along with Durvalumab. They will also receive a one-time treatment of Y-90 radiation. The treatment will follow a set schedule over several cycles, lasting up to 52 weeks after completing the initial treatment.
Where
This trial is running at 1 location in the United States. It is currently recruiting.
Beth Israel Deaconess Medical Center
Boston, Massachusetts